Pressreleases

World Premiere: GCMS-QP2010 Ultra – The Highest Performance in its Class

Increased sensitivity at high scan speeds by over five times / Analysis cycle dramatically reduced / The first environmentally friendly GC-MS.

RF-20A and RF-20Axs – Worldwide Most-Sensitive Fluorescence Detectors

Ultra-high sensitivity detecting trace-level compounds / For fast LC and ultra-fast analysis / Easy maintenance reduces running costs.

LC-30A Nexera – New UHPLC Unsurpassed in High-Speed and High-Resolution Analysis and Productivity

The cleanest and fastest system ever to date / Versatile tool for a multitude of different applications / New components, best materials and technologies.

Pittcon Announces 2011 Technical Program

Highlights: Webcasting, environmental sessions, and Chad A Mirkin.

Chad A Mirkin to Deliver Pittcon 2011 Plenary Lecture

Most cited chemist in the world (Thomson Reuters).

Conferee Registration Opens for Pittcon 2011 Discounts for Early Registration

The Pittcon Registration Committee is pleased to announce that conferee registration is now open for Pittcon 2011, which will be held 13-18 March 2011, at the Georgia World Conference Center (GWCC), Atlanta, Georgia.

quICk finder™ – How do You Clean up Your Samples for IC?

The real challenge in ion chromatography is often sample preparation. There are many techniques available– so which one will do the trick for your sample? Metrohm's new quICk finder™ provides the answer.

Lean Compliance and Adopting a True Risk-Based Approach to Validation

With the increasing need for businesses to reduce cost and demonstrate value, there is a requirement to look at all aspects of the pharmaceutical and biopharmaceutical industry to achieve improvements in efficiency, including how quality and compliance is managed.

Deal Struck for New Investigational Anti-Cancer Drug toTarget Leukaemia and Lymphoma

Cancer Research UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody drug from Merck KGaA, Darmstadt, Germany, called DI-B4.